HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced it has received final clearance and approval from the Florida Agency for Health Care Administration (AHCA) to proceed with the closing of the Dura Medical LLC acquisition. This regulatory approval was a key step for the acquisition.
Dura Medical, a revenue-generating and EBITDA-positive entity, was founded in 2018 and offers a precision approach to treating mental health and chronic pain on Florida's west coast. Its services include Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato, and Stellate Ganglion Blocks.
The clearance from AHCA allows HOPE Therapeutics to move expeditiously toward closing this landmark acquisition, which will integrate Dura's tradition of excellence and commitment to patient care into HOPE's Florida network. Stephen Durand, Dura's founder, will be appointed Director of Florida Clinic Operations for HOPE.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.